FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224717515> ?p ?o ?g. }

• W4224717515 endingPage "4168" @default.
• W4224717515 startingPage "4157" @default.
• W4224717515 abstract "Palbociclib was the only available cyclin-dependent kinase 4/6 inhibitor in China until very recently, and its effect has not been systemically evaluated among Chinese patients. This study aims to assess the efficacy, safety and patient-reported outcomes (PROs) of palbociclib plus endocrine therapy (ET) in real-world China.An ambispective cohort study was conducted on patients with advanced HR+HER2- breast cancer who received palbociclib between July 2018, and November 2020 and were enrolled from 12 hospitals. Treatment patterns, survival outcomes, and safety events were documented, and PROs (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 items [EORTC QLQ-C30] and EuroQoL 5 dimensions [EQ-5D]) were analyzed. The Kaplan-Meier method was used to visualize and estimate the median progression-free survival (mPFS). Log-rank tests, Cox regressions, t tests, and chi-square tests were performed for comparison.A total of 190 patients (median follow-up of 18.0 months) were enrolled. Palbociclib was mostly combined with aromatase inhibitors (66.3%), fulvestrant (32.6%), and tamoxifen (1.1%). The mPFS values were 21.0, 14.0, and 7.0 months with palbociclib administered in first- (n = 83), second- (n = 41) and subsequent-line settings (n = 66), respectively. Endocrine sensitivity was significantly associated with patient prognosis (mPFS: 23.0, 12.0, and 6.0 months for endocrine naïve, acquired, and primary resistant patients, respectively, p < 0.01). The outcome was worse for patients who failed to meet the inclusion criteria of PALOMA-3 than for those who met the criteria (later-line: 6.0 months vs. 9.0 months). The most common adverse events (AEs) were neutropenia (74.2%; grade 3/4: 30.0%), fatigue (48.4%), anemia (32.6%), and thrombocytopenia (22.1%). PRO data suggested that palbociclib plus ET significantly improved cognitive and emotional function, pain symptoms, and overall quality of life.Palbociclib is effective for front-line use and for treating endocrine-sensitive patients in real-world China and is generally well tolerated. The prevalence of AEs in the Chinese population is different from that reported in the PALOMA-2/3 trials." @default.
• W4224717515 created "2022-04-27" @default.
• W4224717515 creator A5003753200 @default.
• W4224717515 creator A5004201927 @default.
• W4224717515 creator A5005778741 @default.
• W4224717515 creator A5010335845 @default.
• W4224717515 creator A5013284962 @default.
• W4224717515 creator A5018021256 @default.
• W4224717515 creator A5022386599 @default.
• W4224717515 creator A5029205668 @default.
• W4224717515 creator A5034181569 @default.
• W4224717515 creator A5039575473 @default.
• W4224717515 creator A5042977387 @default.
• W4224717515 creator A5046767410 @default.
• W4224717515 creator A5062937629 @default.
• W4224717515 creator A5069957454 @default.
• W4224717515 creator A5070148419 @default.
• W4224717515 creator A5073787962 @default.
• W4224717515 creator A5076385892 @default.
• W4224717515 creator A5077534982 @default.
• W4224717515 creator A5085596965 @default.
• W4224717515 creator A5088591085 @default.
• W4224717515 creator A5089436053 @default.
• W4224717515 date "2022-04-25" @default.
• W4224717515 modified "2023-10-14" @default.
• W4224717515 title "Treatment patterns, effectiveness, and patient‐reported outcomes of palbociclib therapy in Chinese patients with advanced breast cancer: A multicenter ambispective real‐world study" @default.
• W4224717515 cites W2019607817 @default.
• W4224717515 cites W2032144589 @default.
• W4224717515 cites W2102620699 @default.
• W4224717515 cites W2105084636 @default.
• W4224717515 cites W2138692147 @default.
• W4224717515 cites W2144790402 @default.
• W4224717515 cites W2167571044 @default.
• W4224717515 cites W2290950904 @default.
• W4224717515 cites W2313479654 @default.
• W4224717515 cites W2337210803 @default.
• W4224717515 cites W2415372857 @default.
• W4224717515 cites W2473786944 @default.
• W4224717515 cites W2514365970 @default.
• W4224717515 cites W2528767298 @default.
• W4224717515 cites W2552099557 @default.
• W4224717515 cites W2558360748 @default.
• W4224717515 cites W2560635244 @default.
• W4224717515 cites W2763875663 @default.
• W4224717515 cites W2791840917 @default.
• W4224717515 cites W2804105316 @default.
• W4224717515 cites W2804524640 @default.
• W4224717515 cites W2805575723 @default.
• W4224717515 cites W2897446380 @default.
• W4224717515 cites W2911188781 @default.
• W4224717515 cites W2927016413 @default.
• W4224717515 cites W2945716039 @default.
• W4224717515 cites W2972049666 @default.
• W4224717515 cites W2976415870 @default.
• W4224717515 cites W2982150569 @default.
• W4224717515 cites W2990323914 @default.
• W4224717515 cites W3031130887 @default.
• W4224717515 cites W3031721927 @default.
• W4224717515 cites W3036616083 @default.
• W4224717515 cites W3082552926 @default.
• W4224717515 cites W3096462237 @default.
• W4224717515 cites W3101320422 @default.
• W4224717515 cites W3103014577 @default.
• W4224717515 cites W3108225937 @default.
• W4224717515 cites W3109881382 @default.
• W4224717515 cites W3115380088 @default.
• W4224717515 cites W3128646645 @default.
• W4224717515 cites W3166403155 @default.
• W4224717515 cites W3167855488 @default.
• W4224717515 cites W4206666777 @default.
• W4224717515 cites W4214852562 @default.
• W4224717515 cites W4224717515 @default.
• W4224717515 doi "https://doi.org/10.1002/cam4.4767" @default.
• W4224717515 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35470572" @default.
• W4224717515 hasPublicationYear "2022" @default.
• W4224717515 type Work @default.
• W4224717515 citedByCount "3" @default.
• W4224717515 countsByYear W42247175152022 @default.
• W4224717515 countsByYear W42247175152023 @default.
• W4224717515 crossrefType "journal-article" @default.
• W4224717515 hasAuthorship W4224717515A5003753200 @default.
• W4224717515 hasAuthorship W4224717515A5004201927 @default.
• W4224717515 hasAuthorship W4224717515A5005778741 @default.
• W4224717515 hasAuthorship W4224717515A5010335845 @default.
• W4224717515 hasAuthorship W4224717515A5013284962 @default.
• W4224717515 hasAuthorship W4224717515A5018021256 @default.
• W4224717515 hasAuthorship W4224717515A5022386599 @default.
• W4224717515 hasAuthorship W4224717515A5029205668 @default.
• W4224717515 hasAuthorship W4224717515A5034181569 @default.
• W4224717515 hasAuthorship W4224717515A5039575473 @default.
• W4224717515 hasAuthorship W4224717515A5042977387 @default.
• W4224717515 hasAuthorship W4224717515A5046767410 @default.
• W4224717515 hasAuthorship W4224717515A5062937629 @default.
• W4224717515 hasAuthorship W4224717515A5069957454 @default.
• W4224717515 hasAuthorship W4224717515A5070148419 @default.
• W4224717515 hasAuthorship W4224717515A5073787962 @default.
• W4224717515 hasAuthorship W4224717515A5076385892 @default.
• W4224717515 hasAuthorship W4224717515A5077534982 @default.

• next